BidaskClub Upgrades Stemline Therapeutics (STML) to Hold

Stemline Therapeutics (NASDAQ:STML) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.

Several other equities analysts also recently issued reports on the stock. ValuEngine raised shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday. HC Wainwright set a $38.00 price target on shares of Stemline Therapeutics and gave the company a “buy” rating in a research note on Wednesday. Roth Capital set a $33.00 price target on shares of Stemline Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 14th. Wedbush reaffirmed an “outperform” rating and set a $22.00 price target on shares of Stemline Therapeutics in a research note on Monday, November 12th. Finally, Zacks Investment Research raised shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 16th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $31.00.

STML stock opened at $12.26 on Friday. The firm has a market cap of $373.02 million, a PE ratio of -4.17 and a beta of 0.58. Stemline Therapeutics has a 52-week low of $10.37 and a 52-week high of $20.55.

Stemline Therapeutics (NASDAQ:STML) last released its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.06). On average, sell-side analysts forecast that Stemline Therapeutics will post -2.81 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. BlueMountain Capital Management LLC acquired a new stake in shares of Stemline Therapeutics during the second quarter worth $137,000. State Board of Administration of Florida Retirement System acquired a new stake in shares of Stemline Therapeutics during the second quarter worth $166,000. MetLife Investment Advisors LLC increased its position in shares of Stemline Therapeutics by 54.6% during the third quarter. MetLife Investment Advisors LLC now owns 18,474 shares of the biopharmaceutical company’s stock worth $307,000 after buying an additional 6,527 shares during the period. Bank of America Corp DE increased its position in shares of Stemline Therapeutics by 97.8% during the second quarter. Bank of America Corp DE now owns 20,548 shares of the biopharmaceutical company’s stock worth $329,000 after buying an additional 10,159 shares during the period. Finally, Algert Global LLC acquired a new stake in shares of Stemline Therapeutics during the second quarter worth $344,000. Institutional investors own 62.39% of the company’s stock.

About Stemline Therapeutics

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

Featured Story: Bull Market

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply